TABLE 1

Comparison of 18F-FDG and 18F-FDHT Uptake in Patients with Advanced, Progressing Prostate Cancer

Patient no.Therapy*Total no. of lesions18F-FDHT18F-FDG
No. of positive lesionsSUVNo. of positive lesionsSUV
1Leuprolide, 17-AAG735.7077.40
2Leuprolide953.4594.70
3Goserelin, testosterone16154.73164.56
4Leuprolide443.3044.63
5Orchiectomy972.9894.12
Oral cyclophosphamide
Pamidronate
Celecoxib
6Leuprolide, testosterone646.5344.05
7Goserelin8810.2887.08
Total5946 (77%)5.28§57 (97%)5.22§
  • * The generic name, trade name, manufacturer, and description are as follows: leuprolide (Lupron; TAP Pharmaceuticals USA), gonadotropin-releasing hormone analog; goserelin (Zoladex; Zeneca USA), gonadotropin-releasing hormone analog; cyclophosphamide (Cytoxan; Bristol MeyersSquibb USA), antineoplastic; pamidronate (Aredia; Novartis USA), bisphosphonate; celecoxib (Celebrex; Searle), nonsteroidal antiinflammatory.

  • Baseline scan.

  • Follow-up scan.

  • § Mean.